GoldenGolden
Shionogi

Shionogi

Japan-based pharmaceutical company focused on the manufacturing and distribution of pharmaceuticals.

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, purchase, manufacture, and sale of pharmaceuticals, as well as pharmaceutical-related businesses. Shionogi's research scientists have discovered therapeutics including naldemedine, rosuvastatin and dolutegravir, and are currently working on many more potential future products. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Shionogi traces it's history back to 1878 when Gisaburo Shiono, Sr., founder of the Company, launched Shiono Gisaburo Shoten a drug wholesaler at the present site of the head office in Doshomachi, Osaka. In 1919, Shiono Gisaburo Shoten and Shiono Seiyakusho merged, and the newly formed company was named Shionogi Shoten. The name was later changed to Shionogi & Co., Ltd.

Shionogi group is made up of 11 companies based in Japan and 6 more based in Taiwan, USA, Hong Kong, United Kingdom, China, and Singapore.

In 2008, Shionogi acquired Sciele Pharma, Inc., a specialty pharmaceutical company based in Atlanta, Georgia, and in 2011, merged it with Shionogi’s small existing development organization in New Jersey. The resulting company became Shionogi Inc., which has the mandate to bring Shionogi innovation to U.S. patients.

Covid-19 Treatment

After the outbreak of Covid-19 in early 2020, clinical trials begun to determine the suitability of Shionogi drugs for the treatment of coronavirus. Various combinations of Shinogi and Toyama Chemical drugs baloxavir marboxil/favipiravir and lopinavir/ritonavir are involved in 2 trials. Baloxavir marboxil is a Cap-dependent endonuclease inhibitor and favipiravir is a guanine analog RNA-dependent RNA polymerase inhibitor approved for influenza.

Timeline

May 3, 2021
Shionogi, Inc appoints Executive Vice President Nathan McCutcheon to the Role of Chief Operating Officer and Senior Vice President Gianine Esposito will join the Executive Committee.
June 5, 1919
Shionogi was founded.

People

Name
Role
LinkedIn

Gisaburo Shiono, Sr

Founder

Isao Teshirogi

President and CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 3, 2021
BioSpace
Shionogi Strengthens U.S. Executive Leadership Team to Support Growth - read this article along with other careers information, tips and advice on BioSpace
BioSpace
May 26, 2020
BioSpace
Tetra Therapeutics today announced that it has entered into a definitive merger agreement for Shionogi & Co., Ltd. to acquire Tetra. With this acquisition, Shionogi will obtain global rights to Tetra's entire portfolio of compounds for
BioSpace
May 19, 2020
BioSpace
Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea's proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017. Under the terms of the agreement, Shionogi

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.